Mesa Laboratories - MLAB Stock Forecast, Price & News

Mesa Laboratories' stock was trading at $328.09 on January 1st, 2022. Since then, MLAB shares have decreased by 55.4% and is now trading at $146.22.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our MLAB earnings forecast.

Mesa Laboratories, Inc. (NASDAQ:MLAB) issued its quarterly earnings data on Thursday, August, 4th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by $1.05. The medical instruments supplier had revenue of $50.45 million for the quarter, compared to analyst estimates of $52.63 million. Mesa Laboratories had a negative net margin of 0.78% and a positive trailing twelve-month return on equity of 5.80%.

Mesa Laboratories declared a quarterly dividend on Wednesday, July 6th. Investors of record on Wednesday, August 31st will be given a dividend of $0.16 per share on Thursday, September 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.44%. The ex-dividend date is Tuesday, August 30th.
Read our dividend analysis for MLAB.

Mesa Laboratories (NASDAQ:MLAB) pays an annual dividend of $0.64 per share and currently has a dividend yield of 0.44%.
Read our dividend analysis for MLAB.

5 employees have rated Mesa Laboratories Chief Executive Officer Gary Owens on Glassdoor.com. Gary Owens has an approval rating of 51% among the company's employees. This puts Gary Owens in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mesa Laboratories investors own include NVIDIA (NVDA), Verizon Communications (VZ), Intel (INTC), Alibaba Group (BABA), Altria Group (MO), Micron Technology (MU), Exxon Mobil (XOM), AbbVie (ABBV), Advanced Micro Devices (AMD) and Becton, Dickinson and (BDX).

Mesa Laboratories trades on the NASDAQ under the ticker symbol "MLAB."

Mesa Laboratories' stock is owned by many different retail and institutional investors. Top institutional shareholders include Conestoga Capital Advisors LLC (9.78%), Royce & Associates LP (5.24%), State Street Corp (3.72%), Kayne Anderson Rudnick Investment Management LLC (2.79%), Principal Financial Group Inc. (2.41%) and Northern Trust Corp (1.68%). Insiders that own company stock include Brian David Archbold, David M Kelly, Evan Guillemin, Gary M Owens, Gregory Dinoia, John Bradley Schmieder, John James Sullivan, John Sakys and Robert V Dwyer.
View institutional ownership trends.

Shares of MLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MLAB stock can currently be purchased for approximately $146.22.

Mesa Laboratories (NASDAQ:MLAB) has a market capitalization of $777.89 million and generates $184.34 million in revenue each year. The medical instruments supplier earns $1.87 million in net income (profit) each year or ($0.30) on an earnings per share basis.

The company employs 506 workers across the globe.

Mesa Laboratories' mailing address is 12100 W 6TH AVE, LAKEWOOD CO, 80228. The official website for the company is www.mesalabs.com. The medical instruments supplier can be reached via phone at (303) 987-8000, via email at investorrelations@mesalabs.com, or via fax at 303-987-8989.